XML 149 R55.htm IDEA: XBRL DOCUMENT
v3.20.4

Collaboration Agreements - AstraZeneca - Strategic Alliances in Cardiovascular and Oncology (Details) | 1 Months Ended | 12 Months Ended |  |
--- | --- | --- | --- | ---
Jun. 30, 2018 | Jan. 31, 2016 | Mar. 31, 2013 USD ($) | Dec. 31, 2020 USD ($) | Dec. 31, 2018 USD ($) | Dec. 31, 2016 USD ($) | Jun. 30, 2019 option | Mar. 31, 2014 USD ($) option milestone
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |
Increase to the transaction price |  |  |  | $ (7,100,000) |  |  |  |
Additions |  |  |  | 4,009,960,000 |  |  |  |
Combined 2018 AZ Agreements |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |
Increase to the transaction price |  |  |  | 5,000,000.0 |  |  |  |
2013 AZ Agreements |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |
Number of options to develop candidates | option |  |  |  |  |  |  |  | 40
Estimated arrangement consideration |  |  |  |  |  |  |  | $ 180,000,000.0
Number of milestones | milestone |  |  |  |  |  |  |  | 3
Option exercise fee |  |  | $ 10,000,000.0 |  |  |  |  |
Termination period |  |  | 90 days |  |  |  |  |
Additions |  |  | $ 240,000,000.0 |  |  | $ 10,000,000.0 |  |
2013 AZ Agreements | VEGF-A product (AZD8601) |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |
Additions |  |  |  |  | $ 30,000,000.0 |  |  |
2013 AZ Agreements | Maximum |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |
Earn-out payments |  |  | 12.00% |  |  |  |  |
2013 AZ Agreements | Development Milestones |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |
Estimated arrangement consideration |  |  |  |  |  |  |  | $ 100,000,000.0
2013 AZ Agreements | Regulatory Milestones |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |
Estimated arrangement consideration |  |  |  |  |  |  |  | 100,000,000.0
2013 AZ Agreements | Commercial Milestones |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |
Estimated arrangement consideration |  |  |  |  |  |  |  | $ 200,000,000.0
VEGF Exercise 2016 |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |
Increase to the transaction price |  |  |  | 400,000 |  |  |  |
2016 AZ Agreement |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |
Termination period |  | 90 days |  |  |  |  |  |
Suspension period |  | 12 months |  |  |  |  |  |
2016 AZ Agreement | Minimum |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |
Tiered royalties |  | 10.00% |  |  |  |  |  |
2016 AZ Agreement | Maximum |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |
Tiered royalties at default rate |  | 20.00% |  |  |  |  |  |
Tiered royalties |  | 30.00% |  |  |  |  |  |
2018 A&R Agreements |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |
Number of options to develop candidates | option |  |  |  |  |  |  | 40 |
Termination period | 90 days |  |  |  |  |  |  |
Estimated reimbursement for clinical supply | VEGF Exercise 2016 |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |
Increase to the transaction price |  |  |  | $ 2,400,000 |  |  |  |

X
- Definition Research And Development Arrangement, Contract To Perform For Others, Earnout Payment, Percent + References No definition available. + Details
Name: | mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersEarnoutPaymentPercent
Namespace Prefix: | mrna_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Research And Development Arrangement, Contract To Perform For Others, Maximum Amount + References No definition available. + Details
Name: | mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount
Namespace Prefix: | mrna_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Research And Development Arrangement, Contract To Perform For Others, Number Of Milestones + References No definition available. + Details
Name: | mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfMilestones
Namespace Prefix: | mrna_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Research And Development Arrangement, Contract To Perform For Others, Number Of Options + References No definition available. + Details
Name: | mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfOptions
Namespace Prefix: | mrna_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Research And Development Arrangement, Contract To Perform For Others, Option Exercise Fee + References No definition available. + Details
Name: | mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersOptionExerciseFee
Namespace Prefix: | mrna_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Research And Development Arrangement, Contract To Perform For Others, Product Suspension Period + References No definition available. + Details
Name: | mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersProductSuspensionPeriod
Namespace Prefix: | mrna_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Research And Development Arrangement, Contract To Perform For Others, Royalty Payment, Default Percent + References No definition available. + Details
Name: | mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltyPaymentDefaultPercent
Namespace Prefix: | mrna_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Research And Development Arrangement, Contract To Perform For Others, Royalty Payment, Percent + References No definition available. + Details
Name: | mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltyPaymentPercent
Namespace Prefix: | mrna_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Research And Development Arrangement, Contract To Perform For Others, Termination Period + References No definition available. + Details
Name: | mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersTerminationPeriod
Namespace Prefix: | mrna_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 10 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045 + Details
Name: | us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in measure of progress which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 10 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045 + Details
Name: | us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_Combined2018AZAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mrna_VEGFAProductAZD8601Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis=mrna_DevelopmentMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis=mrna_RegulatoryMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMilestoneAxis=mrna_CommercialMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_VEGFExercise2016Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_A2016StrategicAllianceWithAstraZenecaIL12Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_AmendedAndRestatedOptionAgreementRelatedAmendedAndRestatedServicesAndCollaborationAgreementWithAstraZenecaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContractWithCustomerBasisOfPricingAxis=mrna_VariableConsiderationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |